Figures computed from official regulatory filings — .
Ownershipinsiders 28.95% · institutions 3.61%
In EUR · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for ABIONYX PHARMA only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension into ophthalmology of CER-001 that is in preclinical trial for the treatment of uveitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was incorporated in 2005 and is headquartered in Balma, France.
Market information source · Oct 19, 2026
Open-market timeline · full history
9 buys3 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Cyrille Tupintrack record | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 55 |
| AMF |
| emmanuel huynh | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 79First in 12mo | AMF |
| emmanuel huynh | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 79First in 12mo | AMF |
| Cyrille Tupintrack record | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 55First in 12mo | AMF |
| ORSAY 53 SAS | Award | $342.9K | AMF |
| DOMUNDI SAS | Award | $114.3K | AMF |
| Caroline DESURMONT | Award | $45.7K | AMF |
| DOMUNDI SAS | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| DOMUNDI SAS | Award | $158.3K | AMF |
| emmanuel huynh | Sell | $37.9K | AMF |
| Christian Chavy | Sell | $39K | AMF |
| Christian Chavy | Sell | $39K | AMF |
| DOMUNDI SAS | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | AMF |
| Cyrille Tupintrack record | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 24 | AMF |
| emmanuel huynh | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 36First in 12mo | AMF |
| Cyrille Tupintrack record | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 44 | AMF |
| Cyrille Tupintrack record | Buy | $10.4K | conv 63 | AMF |
| Cyrille Tupintrack record | Buy | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | conv 45First in 12mo | AMF |
| SERFELIZ SC SC | Award | $282.9K | AMF |
| DOMUNDI SC | Award | $848.6K | AMF |
| Cyrille Tupintrack record | Award | $282.9K | AMF |
| Christian Chavy | Award | $135.8K | AMF |